Hyundai Pharmaceutical Co., Ltd.
Hyundai Pharmaceutical Co., Ltd. is a Private limited company (Ltd.) registered in South Korea under 1308100988, and its current status with Supreme Court Internet Registry (IROS) is active. Its registered address on file is Seoul, South Korea. 5 shareholders are on record for Hyundai Pharmaceutical Co., Ltd., and since every one of them is a company rather than an individual, this particular filing does not on its own establish an ultimate beneficial owner (UBO) — identifying one would mean tracing the ownership of each shareholding company in turn. This profile is sourced directly from Supreme Court Internet Registry (IROS) and was last updated on 1 October 2026.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Five shareholders are currently on record for Hyundai Pharmaceutical Co., Ltd., filed with Supreme Court Internet Registry (IROS).
The largest of these is DFA Emerging Markets Small Cap Series, holding 53.1% — a majority holding — followed by DFA Emerging Markets Core Equity Portfolio at 36.7%; the remaining 3 shareholders shown hold smaller stakes.
The register reports 7 shareholders in total, though only the top 5 by holding are shown in this view.
Because every shareholder shown is a company rather than an individual, the ownership chain continues above this level, and no beneficial owner can be established from this filing alone.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| DFA Emerging Markets Small Cap Series | 53.1% | Supreme Court Internet Registry (IROS) | |
| DFA Emerging Markets Core Equity Portfolio | 36.7% | Supreme Court Internet Registry (IROS) | |
| Dimensional ETF Tr-Dimensional Emerging Core Equity Market ETF | 3.6% | Supreme Court Internet Registry (IROS) | |
| DFA Investment Dimensions-DFA World Ex U.S. Targeted Value Port | 2% | Supreme Court Internet Registry (IROS) | |
| DFA Emerging Markets Sustainability Core 1 Portfolio | 1.9% | Supreme Court Internet Registry (IROS) |
Officers
2
Two officers are currently on record for Hyundai Pharmaceutical Co., Ltd., filed with Supreme Court Internet Registry (IROS). Young-hak Kim and Sang-jun Lee both serve as President.
Management authority at Hyundai Pharmaceutical Co., Ltd. sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control.
The source filing doesn't specify representation authority — whether officers can act individually or must sign jointly to bind the company — so that detail isn't available here.
Group Structure
Hyundai Pharmaceutical Co., Ltd. has no recorded parent company — it sits at the top of its own group structure, with 1 subsidiary recorded beneath it across 1 jurisdiction. Each of these downward relationships is derived rather than filed: resolved by matching entities across the registry network, not stated directly in a single document.
Those 1 subsidiary spans South Korea jurisdiction, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear.
Hyundai Pharmaceutical Co., Ltd.
South Korea
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
Who owns Hyundai Pharmaceutical Co., Ltd.?
Five shareholders are currently on record for Hyundai Pharmaceutical Co., Ltd., filed with Supreme Court Internet Registry (IROS). The largest of these is DFA Emerging Markets Small Cap Series, holding 53.1% — a majority holding — followed by DFA Emerging Markets Core Equity Portfolio at 36.7%; the remaining 3 shareholders shown hold smaller stakes. Because every shareholder shown is a company rather than an individual, the ownership chain continues above this level, and no beneficial owner can be established from this filing alone.
Who is Hyundai Pharmaceutical Co., Ltd.'s UBO (Ultimate Beneficial Owner)?
Every shareholder recorded for Hyundai Pharmaceutical Co., Ltd. is itself a company rather than a natural person, so no Ultimate Beneficial Owner (UBO) is identified at this level; establishing one would require tracing the ownership of each shareholding company in turn.
How many shareholders does Hyundai Pharmaceutical Co., Ltd. have on record?
5 shareholders are shown on record for Hyundai Pharmaceutical Co., Ltd.. The register reports 7 in total; only the top 5 by holding are shown here.
What is Hyundai Pharmaceutical Co., Ltd.'s company registration number?
Hyundai Pharmaceutical Co., Ltd.'s registration number is 1308100988, filed with Supreme Court Internet Registry (IROS) in South Korea. Its current status on the register is active.
Is Hyundai Pharmaceutical Co., Ltd. still an active company?
Hyundai Pharmaceutical Co., Ltd.'s status on Supreme Court Internet Registry (IROS) is listed as active.
What is Hyundai Pharmaceutical Co., Ltd.'s registered address?
The registered address on file for Hyundai Pharmaceutical Co., Ltd. is Seoul, South Korea.
What legal structure is Hyundai Pharmaceutical Co., Ltd. registered as?
Hyundai Pharmaceutical Co., Ltd. is registered as a Private limited company (Ltd.) in South Korea.
Who are the officers/directors of Hyundai Pharmaceutical Co., Ltd.?
Two officers are currently on record for Hyundai Pharmaceutical Co., Ltd., filed with Supreme Court Internet Registry (IROS). Young-hak Kim and Sang-jun Lee both serve as President. Management authority at Hyundai Pharmaceutical Co., Ltd. sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control.
Does Hyundai Pharmaceutical Co., Ltd. have a parent company or subsidiaries?
Hyundai Pharmaceutical Co., Ltd. has no recorded parent company — it sits at the top of its own group structure, with 1 subsidiary recorded beneath it across 1 jurisdiction. Those 1 subsidiary spans South Korea jurisdiction, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear.
Can Zavia monitor changes to Hyundai Pharmaceutical Co., Ltd.'s ownership over time?
This profile reflects a point-in-time snapshot from Supreme Court Internet Registry (IROS). Zavia's monitoring API can track changes to Hyundai Pharmaceutical Co., Ltd.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Hyundai Pharmaceutical Co., Ltd.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including South Korea, so records like Hyundai Pharmaceutical Co., Ltd.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Supreme Court Internet Registry (IROS) and was last synced on 1 October 2026.